Loading...
Although treatment of malignant gliomas with combination temozolomide chemotherapy, irradiation, and surgery has improved survival, prognosis remains poor and recurrence inevitable. Therefore, the search for novel therapeutic targets continues. Bevacizumab, a human monoclonal antibody, targets vascular endothelial growth factor (VEGF), which mediates angiogenesis in gliomas and other cancers. In this study, researchers retrospectively assessed recurrence patterns in 55 patients with recurrent malignant gliomas who received bevacizumab (along with various chemotherapy regimens) and in 19 patients treated with chemotherapy regimens that did not contain bevacizumab.
Among the 44 patients with radiographic data, the radiographic response rate (i…